Exosomal hsa-miR-21-5p is a biomarker for breast cancer diagnosis

Min Liu¹²³, Fei Mo¹²³, Xiaohan Song¹, Yun He², Yan Yuan³, Jiaoyan Yan³, Ye Yang³, Jian Huang² and Shu Zhang²³

¹ Department of Laboratory Medicine, Sichuan Maternal and Child Health Hospital, Chengdu, Sichuan Province, China
² Department of Clinical Laboratory, Affiliated Hospital of Guizhou Medical University Guiyang, Guizhou Province, China
³ Department of Basic Clinical Laboratory Medicine, School of Clinical Laboratory Science, Guizhou Medical University, Guiyang, Guizhou Province, China

ABSTRACT

Purpose. Breast cancer (BC) is characterized by concealed onset, delayed diagnosis, and high fatality rates making it particularly dangerous to patients’ health. The purpose of this study was to use comprehensive bioinformatics analysis and experimental verification to find a new biomarker for BC diagnosis.

Methods. We comprehensively analyzed microRNA (miRNA) and mRNA expression profiles from the Gene Expression Omnibus (GEO) and screened out differentially-expressed (DE) miRNAs and mRNAs. We used the miRNet website to predict potential DE-miRNA target genes. Using the Database for Annotation, Visualization and Integrated Discovery (DAVID), we performed Gene Ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses on overlapping potential target genes and DE-mRNAs. The protein-protein interaction (PPI) network was then established. The miRNA-mRNA regulatory network was constructed using Cytoscape and the analysis results were visualized. We verified the expression of the most up-regulated DE-miRNA using reverse transcription and a quantitative polymerase chain reaction in BC tissue. The diagnostic value of the most up-regulated DE-miRNA was further explored across three levels: plasma-derived exosomes, cells, and cell exosomes.

Results. Our comprehensive bioinformatics analysis and experimental results showed that hsa-miR-21-5p was significantly up-regulated in BC tissue, cells, and exosomes. Our results also revealed that tumor-derived hsa-miR-21-5p could be packaged in exosomes and released into peripheral blood. Additionally, when evaluating the diagnostic value of plasma exosomal hsa-miR-21-5p, we found that it was significantly up-regulated in BC patients. Receiver operating characteristic (ROC) analysis also confirmed that hsa-miR-21-5p could effectively distinguish healthy people from BC patients. The sensitivity and specificity were 86.7% and 93.3%, respectively.

Conclusion. This study’s results showed that plasma exosomal hsa-miR-21-5p could be used as a biomarker for BC diagnosis.
INTRODUCTION

Breast cancer (BC) is a malignant tumor that originates from the glandular epithelium of the breast. Due to the lack of typical and specific clinical symptoms and signs in the early stage, most patients present with symptoms and are diagnosed in middle and late stages, making BC particularly dangerous. Although BC is the leading cause of cancer-related death in women (Bray et al., 2018), the current detection methods used to clinically diagnose BC are inadequate to a certain extent. Specifically, pathologic examinations are invasive and imaging examinations are not accurate. The sensitivity and/or specificity of existing biomarkers requires further analysis, which limits their application in BC diagnosis (Bevers et al., 2018; Holloway et al., 2010; Lian et al., 2019). Therefore, new biomarkers are needed to promptly detect and diagnose BC in order to improve the rate of survival of BC patients (De Santis et al., 2016).

MicroRNAs (miRNAs) are non-coding small RNAs in eukaryotes that are approximately 21 to 23 nucleotides long. MiRNAs have been found to be heavily dysregulated in many types of malignant tumors and to participate in a series of important biological activities, such as tumor cell proliferation (Chen et al., 2020; Roy et al., 2018; Wei & Gao, 2019), migration (Chen et al., 2020; Wei & Gao, 2019; Xu, Yu & Liu, 2020; Yu et al., 2019), and apoptosis (Chen et al., 2019; Kasinski & Slack, 2011). It has been reported that miR-1246 targets CaV1 regulation and acts on the PDGFβ receptor in ovarian cancer cells, thereby inhibiting cell proliferation (Kanlikilicer et al., 2018). Hong et al. (2019) found that miR-204-5p directly regulates PIK3Cβ expression and the downstream PI3K/Akt signal pathway in BC, hence affecting BC growth and metastasis. Therefore, understanding tumor-related miRNAs might help reveal the molecular mechanisms underlying tumor development and formation, and provide new insights for clinical tumor diagnosis and treatment.

Exosomes are lipid bimolecular vesicles with a diameter of 30–150 nm (Deng & Miller, 2019). Exosomes exist in plasma, urine, saliva, and cell supernatant culture medium, and are released into the extracellular space by a variety of cells during exocytosis (Hesari et al., 2018). They contain receptors on their lipid bilayer membrane and carry proteins, lipids, mRNAs, miRNAs, and long non-coding RNAs derived from the original inside cells to protect them from degradation (De Veirman et al., 2016; Di Pace et al., 2020; Wang, Zheng & Zhao, 2016). Recently, a growing body of evidence shows that exosomal nucleic acids can act as novel biomarkers to diagnosis many types of diseases (Deng, Magee & Zhang, 2017). Exosome-derived miR-192, miR-122, and miR-30a showed excellent diagnostic value in identifying alcoholic hepatitis (AH), confirming that they are promising biomarkers for AH diagnosis (Momen-Heravi et al., 2015). Chen et al. (2015) found that plasma exosomal miR-214 is a potential biomarker for liver fibrosis.

High throughput microarray technology for expression profiling has become widely-used in the study of cancer genes and the identification of new biomarkers (Huang & Gao, 2018). In this study, we comprehensively analyzed the expression profile of the Gene Expression Omnibus (GEO) database to obtain differentially-expressed (DE) miRNAs and mRNAs. We used the miRNet website to predict potential DE-miRNA target genes. Gene Ontology (GO) annotation and Kyoto Encyclopedia of Genes and Genomes (KEGG)
pathway analysis were performed on the intersection of potential target genes and DE-mRNAs using the Database for Annotation, Visualization and Integrated Discovery (DAVID) database, and the protein–protein interaction (PPI) network was constructed using the STRING database. Additionally, the miRNA-mRNA regulatory network was constructed using Cytoscape and the results were visualized. Using our analysis, we explored the expression and diagnostic value of significantly different miRNAs across three specimen types (tissue, plasma, and cellular exosomes). This provided a basis for studying the molecular mechanisms underlying BC progression and identifying reliable biomarkers for diagnosis (Fig. 1).
MATERIALS & METHODS

Microarray dataset acquisition
The miRNA expression profile of GSE97811 and the mRNA expression profile of GSE29044 were downloaded from the GEO database (http://www.ncbi.nlm.nih.gov/geo/). GSE97811 was detected using the GPL21263 3D-Gene Human miRNA V21_1.0.0 platform, which included 16 normal controls and 45 BC tissues. GSE29044 was detected using the GPL570 [HG- U133_Plus_2] Affymetrix Human Genome U133Plus 2.0 Array platform, which included 36 normal controls and 73 BC tissues.

Identifying DE-miRNAs and DE-mRNAs
The GEO2R online tool (https://www.ncbi.nlm.nih.gov/geo/info/geo2r.html) was used to analyze and filter miRNAs (DE-miRNAs), which were significantly different in GSE97811, and mRNAs (DE-mRNAs), which were significantly different in GSE29044. |log2FC| ≥2 and P < 0.05 were considered the cutoff values.

Predicting DE-miRNAs targeting mRNAs and acquisition of overlapping mRNAs
We used miRNet (https://www.mirnet.ca/) to predict the target mRNAs of the DE-miRNAs (Fan et al., 2016). The predicted target mRNAs were matched with the DE-mRNAs obtained by microarray analysis, and the overlapping mRNAs were obtained using the Venn online tool (http://bioinformatics.psb.ugent.be/webtools/Venn/).

Functional enrichment analysis
GO and KEGG pathway analyses were performed using the DAVID Bioinformatics Resource (version 6.8, https://david.ncifcrf.gov/), a database for annotation, visualization, and integrated discovery (Huang, Sherman & Lempicki, 2009a; Huang, Sherman & Lempicki, 2009b). The DAVID Bioinformatics Resource was helpful for understanding the biological functions and possible pathways of overlapping target genes. The results were visualized using the R software package (ggplot2 and Cairo). P < 0.05 was considered statistically significant.

Constructing the PPI and miRNA-mRNA network
We used STRING (version 11.0, https://string-db.org/cgi/network.pl) to draw the PPI network, and we set the cut-off criterion to a confidence score >0.4 (Szklarczyk et al., 2019). We used the Cytoscape ‘cytoHubba’ plug-in (v3.6.0, http://cytoscape.org) to screen the hub genes by degree value, then constructed and identified the top 10 miRNA-mRNA networks using the hub genes and DE-miRNAs.

Expressing potential target genes and drawing a Kaplan-Meier curve
We used UALCAN (http://ualcan.path.uab.edu/index.html) and the human protein atlas (HPA, https://www.proteinatlas.org/) to search for the expression of potential miRNA target genes with the most significant differences (Chandrashekar et al., 2017; Uhlen et al., 2017). The Kaplan Meier Plotter online tool (http://kmplot.com/analysis/) was used to analyze data from 1,078 BC samples taken from the Cancer Genome Atlas database (Nagy
et al., 2018). Using the tool we explored the relationship between the target genes and the BC patients’ prognosis.

**Sample collection**

This study was approved by the Ethics Committee of the Affiliated Hospital of Guizhou Medical University and carried out in accordance with the ethical standards of the Declaration of Helsinki (2019032K and 2019033K). All patients signed informed consent. The samples included surgical tissue and peripheral blood samples from 30 patients with BC (all confirmed by pathologic evaluation, all females, age 36–69 years, with an average age of 55.5 years). The surgical tissues included BC and adjacent tissue (3 ~5 cm from the tumor margin). Simultaneously, peripheral blood samples were collected from 30 healthy patients (all females, age 25–65 years, with an average of 45.5 years). Six peripheral blood samples were each obtained from patients with liver cancer (three males and three females, age 45–70 years, with an average age of 62.5 years), lung cancer (three males and three females, age 47–75 years, with an average age of 68.3 years), cervical cancer (all females, age 47–60 years, with an average age of 53.2 years), and ovarian cancer (all females, age 47–58 years, with an average age of 51.2 years).

**Cell culture**

Human non-tumorigenic epithelial cell line MCF 10A and BC cells MDA-MB-23, MCF7, and BT474 were purchased from the American Type Culture Collection (ATCC). MCF10A cells were cultured in an MEGM kit (CC3150; Lonza) with 100 ng/mL cholera toxin (C8052; Sigma). MDA-MB-231 and MCF7 cells were cultured in DMEM medium (Gibco, C11995500BT) and BT474 was cultured in RPMI-1640 medium (C11875500BT; Gibco). We added 10% exosome-free fetal bovine plasma and antibiotics (100 U/mL of penicillin and 100 U/mL of streptomycin) to the medium, and cultured it at 37 °C in a 5% CO₂ incubator.

**Isolating and identifying exosomes**

Peripheral blood was centrifuged at 4 °C for 1200 ×g for 10 min to obtain plasma. Plasma-derived exosomes were isolated through differential ultracentrifugation (Théry et al., 2006). The exosome morphology was analyzed by transmission electron microscopy (TEM). Ten minutes after 10 µL of the exosomes were pipetted onto a grid coated with formvar and carbon at room temperature, excess fluid was removed, and the sample was negatively stained with 3% phosphotungstic acid (pH 6.8) for 5 min. Finally, the samples were analyzed by TEM. The exosome concentration and size range were identified using a NanoSight NS300 system (NanoSight, Salisbury, United Kingdom) supplied with a fast video capture and Nanoparticle Tracking Analysis (NTA) software. Before performing the experiments, the instrument was calibrated with 100 nm polystyrene beads (Thermo Scientific, Waltham, MA, USA). The samples were captured for 60 s at room temperature. NTA software processed the video captures and measured the particle concentration (particles/ml) and size distribution (in nanometer). Each specimen was measured three times.
Western blotting
The total exosomal proteins were extracted and then subjected to SDS-PAGE electrophoresis to transfer the protein to the PVDF membrane. The 5% skimmed milk was sealed at room temperature for 2 h, washed three times with TBST, incubated overnight at 4 °C with TSG101 (ab125011; Abcam) and Calnexin (ab133615; Abcam) antibody, and incubated for 1 h in HRP-labeled secondary antibody (SA00001-2; Proteintech) at room temperature. After washing three times, the exosome protein marker expression was detected using ECL luminescence and Calnexin as the negative control.

Reverse transcription and quantitative polymerase chain reaction (RT-qPCR) analysis
Total RNA was extracted from tissues, cells, and exosomes using the TRIzol™ Reagent (Invitrogen, 11596026) according to the manufacturer’s instructions. The primers used in the study (Table S1) were synthesized by Sangon Biotech (Shanghai, China). Reverse transcription was performed in accordance with the PrimeScript™ RT Reagent Kit (RR037A; TaKaRa) manufacturer’s instructions. We performed DE-miRNA RT-qPCR using TB Green® PreMix Ex Taq™ II (RR820A; TaKaRa) with corresponding forward and reverse primers. U6 snRNA was used for normalization, and DE-miRNA relative expression was calculated using the $2^{-\Delta\Delta Ct}$ method.

ROC curve analysis of the most significant difference in miRNA performance in BC diagnosis
RT-qPCR was used to determine the expression of DE-miRNAs in BC and adjacent tissue, and the miRNAs with the most significant differences were selected. We used a receiver operating characteristic (ROC) curve to evaluate the miRNA values as a diagnostic marker for BC. The Youden index was used to determine the cut-off value of the most significant difference in the relative expression of DE-miRNA. At the same time, we randomly selected samples from six healthy people, six BC patients, six liver cancer patients, six lung cancer patients, six cervical cancer patients, and six ovarian cancer patients to detect the miRNA expression with the most significant difference in plasma-derived exosomes.

Statistical analysis
Statistical analysis was performed using SPSS24.0 software. A paired sample t test was used to compare hsa-miR-21-5p expression in BC and adjacent tissue, and in plasma-derived exosomes of BC patients before and after surgery. The Pearson correlation was used to analyze the correlation between hsa-miR-21-5p in plasma-derived exosomes and cancer tissues. $P < 0.05$ was considered statistically significant.

RESULTS
Identifying DE-miRNAs and DE-mRNAs
The GEO2R online tool was used to analyze the GEO datasets. Of the 18 DE-miRNAs screened from the miRNA expression profile dataset GSE97811, six miRNAs were up-regulated and 12 miRNAs were down-regulated (Fig. 2A). After analyzing the mRNA
expression dataset GSE29044, we screened 479 DE-mRNAs: 134 mRNAs were up-regulated and 345 mRNAs were down-regulated (Fig. 2B).

**Predicting target genes and overlapping mRNA acquisition**

The 2,064 target mRNAs of the DE-miRNAs predicted by miRNet (Table 1) were matched with the 479 DE-mRNAs obtained by GSE29044, and 52 overlapping mRNAs were identified for further analysis (Fig. 3).

**Functional enrichment analysis of overlapping mRNAs**

Fifty-two overlapping mRNAs were analyzed. Biological process (BP) included the positive regulation of transcription from RNA polymerase II promoter, cell division, and cell proliferation (Fig. 4A). Molecular function (MF) mainly included ATP and chromatin binding (Fig. 4B). The cellular components (CC) were mainly receptor complexes and proteinaceous extracellular matrix (Fig. 4C). Additionally, the KEGG pathway was mainly enriched in cancer-related pathways (Fig. 4D), such as miRNAs in cancer (hsa05206), proteoglycans in cancer (hsa05205), and the p53 signaling pathway (hsa04115).

**Constructing the PPI and miRNA-mRNA networks**

STRING was used to construct the PPI network of 52 overlapping mRNAs, which included 52 nodes and 81 edges (Fig. 5A). The Cytoscape cytoHubba plug-in was used to identify the top 15 hub genes in this network (Table 2). These 15 hub genes and DE-miRNAs were used to draw the miRNA-mRNA network, which included has-miR-4645-3p, hsa-miR-205-5p, hsa-miR-21-5p, hsa-miR-22-3p, and hsa-miR-425-5p (Fig. 5B), in which EGFR, transforming growth factor beta receptor III (TGFβR3), CDK1, and KIF2C were potential...
### Table 1  Eighteen differentially expressed miRNAs and predicted number of target genes.

| miRNAs          | Number of target genes | Type |
|-----------------|------------------------|------|
| has-miR-22-3p   | 163                    | Up   |
| has-miR-429     | 151                    | Up   |
| has-miR-96-5p   | 201                    | Up   |
| has-miR-21-5p   | 612                    | Up   |
| has-miR-425-5p  | 144                    | Up   |
| has-miR-182-5p  | 179                    | Up   |
| has-miR-4256    | 35                     | Down |
| has-miR-5481    | 172                    | Down |
| has-miR-3201    | 40                     | Down |
| has-miR-380-3p  | 77                     | Down |
| has-miR-5007-5p | 112                    | Down |
| has-miR-4772-5p | 58                     | Down |
| has-miR-136-3p  | 48                     | Down |
| has-miR-219a-5p | 46                     | Down |
| has-miR-208b-5p | 111                    | Down |
| has-miR-4650-5p | 86                     | Down |
| has-miR-4645-3p | 71                     | Down |
| has-miR-205-5p  | 182                    | Down |

Figure 3  Venn diagrams of target mRNAs and DE-mRNAs. Target, predicted target mRNAs; Diff, DE-mRNAs obtained by GSE29044.

Target genes of has-miR-21-5p, has-miR-205-5p, and has-miR-4645-3p, respectively (Fig. 5C). No potential target genes of has-miR-22-3p or has-miR-425-5p were found.

**hsa-miR-21-5p expression was significantly up-regulated in BC tissue and cells**

Based on our analysis, we selected has-miR-21-5p for follow-up study because it had the greatest up-regulated expression. The RT-qPCR results showed that has-miR-21-5p expression was up-regulated in BC tissue when compared with adjacent tissue (Fig. 6A),
Figure 4  The results of GO and KEGG analyses of 52 overlapping mRNAs. (A) The top 10 GO terms in the BP results of 52 overlapping mRNAs. (B) The top 10 GO terms in the MF results of 52 overlapping mRNAs. (C) The top 10 GO terms in the CC results of 52 overlapping mRNAs. (D) The results of KEGG pathway enrichment analysis of 52 overlapping mRNAs.

Table 2  The top 15 mRNAs in the PPI network and their degree.

| mRNA  | Degree | Type |
|-------|--------|------|
| EZH2  | 13     | Up   |
| TOP2A | 11     | Up   |
| CCNA2 | 11     | Up   |
| CDK1  | 11     | Up   |
| RRM2  | 10     | Up   |
| BIRC3 | 10     | Up   |
| KIF2C | 9      | Up   |
| CENPF | 9      | Up   |
| CEP55 | 9      | Up   |
| BUB1B | 9      | Up   |
| MMP9  | 6      | Up   |
| EGFR  | 13     | Down |
| CAV1  | 3      | Down |
| TGFBR3| 3      | Down |
| DMD   | 3      | Down |

which was consistent with our results from the GEO database (Fig. 6B). Additionally, our results showed that hsa-miR-21-5p expression in BC cells and the derived exosomes was up-regulated, especially in MDA-MB-231 cells (Fig. 6C).
Figure 5  Construction of PPI and miRNA-mRNA networks. PPI: protein–protein interaction. (A) PPI network of 52 overlapping mRNAs. (B) The miRNA-mRNA network constructed by 15 hub genes and DE-miRNAs. (C) The identified degree ranks the top 10 miRNA-mRNA networks.

Exosome identification

After the exosomes were isolated from plasma, we used TEM to examine the exosomes and found that they were typically dish-shaped and contained low electron density substances (Fig. 7A). NTA showed that the exosome particle size was between 100 and 300 nm and was relatively uniform, and the diameter was approximately 128 nm (Fig. 7B). Western blotting detected exosome protein marker TSG101. Calnexin was not expressed (Fig. 7C). The results indicated that the exosomes were successfully extracted.

Elevated plasma hsa-miR-21-5p was tumor-derived and packaged into exosomes

RT-qPCR was used to determine hsa-miR-21-5p expression in the plasma-derived exosomes of BC patients before and after tumor resection. The expression was significantly down-regulated after tumor resection (Fig. 8A). Additionally, we found that plasma exosomal hsa-miR-21-5p expression in BC patients was positively correlated with has-miR-21-5p expression in BC tissue (Fig. 8B). We then cultured MDA-MB-231 and MCF7
The expression of hsa-miR-21-5p was significantly up-regulated in breast cancer tissues and breast cancer cells. (A) The expression of hsa-miR-21-5p in 30 pairs of breast cancer tissues and corresponding adjacent tissues. (B) The expression of hsa-miR-21-5p in GSE97811. (C) The expression of hsa-miR-21-5p in breast cancer cell lines. *P < 0.05 vs. a MCF10A cell group; #P < 0.05 vs. a MCF10A exosome group.

Figure 6  The expression of hsa-miR-21-5p was significantly up-regulated in breast cancer tissues and breast cancer cells. (A) The expression of hsa-miR-21-5p in 30 pairs of breast cancer tissues and corresponding adjacent tissues. (B) The expression of hsa-miR-21-5p in GSE97811. (C) The expression of hsa-miR-21-5p in breast cancer cell lines. *P < 0.05 vs. a MCF10A cell group; #P < 0.05 vs. a MCF10A exosome group.

Full-size DOI: 10.7717/peerj.12147/fig-6

cells, collected exosomes in the culture medium at different time points, and noted that exosome hsa-miR-21-5p expression in the two cells’ culture media increased over time (Fig. 8C).

**Exosomal hsa-miR-21-5p was significantly up-regulated in BC patient plasma and had remarkable diagnostic value**

When evaluating the diagnostic value of plasma exosomal hsa-miR-21-5p, we found that its expression was most significantly up-regulated in BC patients, but there was no
significant difference in plasma-derived exosomes across lung, liver, cervical, and ovarian cancer patients (Fig. 9A). Additionally, ROC curve analysis showed that plasma exosomal hsa-miR-21-5p could distinguish healthy people from BC patients, with an area under the curve of 0.961 (95% CI [0.920–1.00], \( P < 0.05 \)), and a sensitivity and specificity of 86.7% and 93.3%, respectively (Fig. 9B).

**Down-regulated expression of target genes TGF\(\beta\)R3 and EGFR in BC**

The UALCAN analysis results showed that the expression of TGF\(\beta\)R3 and EGFR, the potential hsa-miR-21-5p target genes, was lower in BC tissue than in normal tissue. There was no significant difference in TGF\(\beta\)R3 expression across different BC stages (Figs. 10A–10B). The results of our HPA database analysis showed that at the protein level, hsa-miR-21-5p’s potential target genes (TGF\(\beta\)R3 and EGFR) were lower in BC tissue than in normal tissue (Fig. 10C).

**TGF\(\beta\)R3 is associated with overall survival (OS) in BC patients**

The Kaplan-Meier curve showed that hsa-miR-21-5p’s potential target gene, TGF\(\beta\)R3, was significantly correlated with the OS of BC patients. Based on the log-rank test, we found no significant differences in the OS between EGFR and BC patients (Figs. 11A–11B).
**DISCUSSION**

BC is one of the most common malignant tumors in women. Its morbidity and mortality rates increase every year (Bray et al., 2018), making it the number one threat to women’s health. Therefore, BC diagnosis, treatment, and prognosis have become the focus of contemporary scholars. With recent and continuous developments and advances in gene detection, microarray and high-throughput sequencing technology play an increasingly important role in investigating biomarkers related to tumor diagnosis, treatment, and prognosis (Liu et al., 2020). Bioinformatic analysis of BC miRNA and mRNA expression profiles could quickly and effectively help us identify biomarkers for BC diagnosis.
Figure 9  The expression of the exosome hsa-miR-21-5p of plasma and its diagnostic value. (A) hsa-miR-21-5p in plasma exosomes of other cancer patients, HC, healthy control; BC, breast cancer; LIHC, liver hepatocellular carcinoma; LCa, lung cancer; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; OV, ovarian serous cystadenocarcinoma. (B) An ROC curve was used to analyze the sensitivity and specificity of hsa-miR-21-5p in the diagnosis of breast cancer. *P < 0.05; ns, no significance.

Full-size DOI: 10.7717/peerj.12147/fig-9

Figure 10  The expression of TGFβR3 and EGFR in breast cancer tissues. (A) The expression of TGFβR3 in breast cancer patients of different stages. *P < 0.05 vs. a Normal group. (B) The expression of EGFR in breast cancer tissues. (C) The expression of TGFβR3 and EGFR in the tissues of breast cancer patients.

Full-size DOI: 10.7717/peerj.12147/fig-10
In this study, we analyzed two datasets from the GEO database and identified 18 DE-miRNAs and 479 DE-mRNAs. After constructing the miRNA-mRNA regulatory network, we screened and selected hsa-miR-21-5p, the core network and the most up-regulated, as the subject of follow-up research. Our experimental verification results were consistent with trends in bioinformatics analysis, indicating that the hsa-miR-21-5p expression was up-regulated in tissues and plasma-derived exosomes of BC patients and in the BC cells and exosomes of cell culture media. Previous studies on miRNA-21 mainly concentrated on peripheral blood (Zhou et al., 2018) and tissue (Gao et al., 2012). The results of this study were also consistent with those of Wu, Zhu & Mo (2009). Additionally, we further verified the hsa-miR-21-5p expression in exosomes. We found that hsa-miR-21-5p expression in BC tissues was positively correlated with its expression in plasma-derived exosomes. hsa-miR-21-5p expression in plasma-derived exosomes decreased post-operatively, indicating that tumors caused the increase in plasma-derived exosomal hsa-miR-21-5p. This enriched the study of BC miRNA-21 from the perspective of plasma-derived exosomes. Moreover, our results showed that hsa-miR-21-5p’s sensitivity and specificity in BC diagnosis were 86.7% and 93.3%, respectively. Additionally, there was no significant difference in the hsa-miR-21-5p expression in plasma-derived exosomes in lung, liver, cervical, and ovarian cancer patients. This finding further confirms that plasma-derived exosomal hsa-miR-21-5p has the potential to serve as a biomarker for BC diagnosis.

In order to further explore hsa-miR-21-5p’s mechanism in BC, we used bioinformatics prediction to obtain two potential target genes: EGFR and TGFβR3. Our results show that at the protein and gene level, both EGFR and TGFβR3 expression was down-regulated in BC patient tissue. We speculated that their low expression may have been caused by the negative
regulation of hsa-miR-21-5p. *TGFβR3* is often used as a tumor suppressor gene for various cancers, including lung cancer (*Liu et al., 2018*), pancreatic cancer (*Hou et al., 2021*), and head and neck cancer (*Fang et al., 2020*). When a tumor progresses, *TGFβR3* expression decreases and is associated with a poor patient prognosis (*Hou et al., 2021*). *TGFβR3*, also known as betaglycan, is the largest kind of transmembrane glycoprotein distributed on the cell surface. This gene is located on human chromosome 1p33-p32 and is the most abundant receptor in transforming growth factor-β (*TGFβ*) signal transduction (*Hou et al., 2021*). It plays a biological role by binding to specific receptors on the cell membrane.

We analyzed *TGFβR3 expression* in 1,065 BC patients in the UALCAN database. Our results showed no significant relationship between *TGFβR3* expression and the patients’ BC stage (*P* > 0.05). *Dong et al.’s* (2007) study of BC samples showed that the loss of *TGFβR3* expression was related to BC progression and its expression was significantly correlated with the BC stage (*P* < 0.05). Our results were different from those of *Dong et al. (2007)*, but there are a number of potential explanations for this. For example, *Dong et al. (2007)* did not include the BC patients’ clinical information, such as age and race. This data could not be analyzed with the subjects included in the UALCAN database leading to inconsistent results. Our initial analysis showed that BC is a highly heterogeneous disease. *Russnes et al. (2011)* found clear heterogeneity across estrogen receptor-positive (ER*) tumors using microarray analysis at the genome, transcriptome, and epigenetic levels. *Baretta, Olopade & Huo (2015)* evaluated the prognostic impact of heterogeneity in hormone-receptor status in bilateral synchronous (SBC) and metachronous breast cancer (MBC) patients. In both patient cohorts they found that heterogeneity in hormone-receptor status could be used to predict OS and BC-specific It is possible that low *TGFβR3* expression may reduce the binding rate of ligand TGF-β, which survival. ER status had a greater prognostic value compared to progesterone receptor (PR) status. in turn reduces the active signal transmitted to downstream genes, leading to a decrease in the tumor suppressor effect of the TGF-β pathway and ultimately leads to a poor prognosis for BC patients.

**CONCLUSION**

In conclusion, our study demonstrated that the plasma-derived exosome hsa-miR-21-5p could be used as a biomarker for BC diagnosis.

**Abbreviations**

| Abbreviation | Description |
|--------------|-------------|
| miRNA        | microRNA    |
| GEO          | Gene Expression Omnibus |
| DE           | differentially-expressed |
| DE miRNA     | differentially-expressed microRNA |
| DE-mRNA      | differentially-expressed mRNA |
| GO           | Gene Ontology |
| KEGG         | Kyoto Encyclopedia of Genes and Genomes |
| PPI          | protein–protein interaction |
| TEM          | transmission scanning electron microscope |
| NTA          | nanoparticle tracking analysis |
RT-qPCR  reverse transcription and quantitative polymerase chain reaction  
ROC    receiver operating characteristic  
BP     biological process  
MF     molecular function  
CC     cellular components  
OS     overall survival time  
HC     healthy control  
BC     breast cancer  
LIHC   liver hepatocellular carcinoma  
LCa    lung cancer  
CESC   cervical squamous cell carcinoma and endocervical adenocarcinoma  
OV     ovarian serous cystadenocarcinoma

**ADDITIONAL INFORMATION AND DECLARATIONS**

**Funding**
This project is supported by the National Natural Science Foundation of China (No.81860723 and 81960589), the Postdoctoral Science Foundation of China (No.2018M643862), the Science and Technology Fund of Guizhou Provincial Health and Family Planning Commission (No. gzwjkj2018-1-073), Science and Traditional Chinese Medicine, National Medicine Science and Technology Fund (No. QZYY-2018-2019) and Guizhou Science and Technology Plan Project (Guizhou Science and Technology Support [2021] General 097). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Grant Disclosures**
The following grant information was disclosed by the authors:
National Natural Science Foundation of China: 81860723, 81960589.
The Postdoctoral Science Foundation of China: 2018M643862.
Science and Technology Fund of Guizhou Provincial Health and Family Planning Commission: gzwjkj2018-1-073.
Science and Traditional Chinese Medicine.
National Medicine Science and Technology Fund: QZYY-2018-2019.
Guizhou Science and Technology Plan Project (Guizhou Science and Technology Support [2021] General 097).

**Competing Interests**
The authors declare there are no competing interests.

**Author Contributions**
• Min Liu conceived and designed the experiments, performed the experiments, analyzed the data, prepared figures and/or tables, authored or reviewed drafts of the paper, and approved the final draft.
• Fei Mo, Xiaohan Song and Yan Yuan analyzed the data, prepared figures and/or tables, and approved the final draft.
• Yun He performed the experiments, analyzed the data, authored or reviewed drafts of the paper, and approved the final draft.
• Jiaoyan Yan and Ye Yang performed the experiments, authored or reviewed drafts of the paper, and approved the final draft.
• Jian Huang and Shu Zhang conceived and designed the experiments, prepared figures and/or tables, authored or reviewed drafts of the paper, and approved the final draft.

Human Ethics
The following information was supplied relating to ethical approvals (i.e., approving body and any reference numbers):

The Ethics Committee of the Affiliated Hospital of Guizhou Medical University approval to carry out the study within its facilities (Ethical Application NO. 2019032K and NO. 2019033K).

Data Availability
The following information was supplied regarding data availability:

The raw data are available at GEO: GSE29044 and GSE97811.

Supplemental Information
Supplemental information for this article can be found online at http://dx.doi.org/10.7717/peerj.12147#supplemental-information.

REFERENCES

Baretta Z, Olopade OI, Huo D. 2015. Heterogeneity in hormone-receptor status and survival outcomes among women with synchronous and metachronous bilateral breast cancers. Breast 24:131–136 DOI 10.1016/j.breast.2014.12.001.

Bevers TB, Helvie M, Bonaccio E, Calhoun KE, Daly MB, Farrar WB, Garber JE, Gray R, Greenberg CC, Greenup R, Hansen NM, Harris RE, Heerdt AS, Helsten T, Hodgkiss L, Hoyt TL, Huff JG, Jacobs L, Lehman CD, Monsees B, Niell BL, Parker CC, Pearlman M, Philpotts L, Shepardson LB, Smith ML, Stein M, Tumyan L, Williams C, Bergman MA, Kumar R. 2018. Breast cancer screening and diagnosis, version 3.2018, NCCN clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network 16:1362–1389 DOI 10.6004/jnccn.2018.0083.

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. 2018. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians 68:394–424 DOI 10.3322/caac.21492.

Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi B, Varambally S. 2017. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia 19:649–658 DOI 10.1016/j.neo.2017.05.002.

Chen L, Chen R, Kemper S, Charrier A, Brigstock DR. 2015. Suppression of fibrogenic signaling in hepatic stellate cells by Twist1-dependent microRNA-214 expression:
role of exosomes in horizontal transfer of Twist1. *American Journal of Physiology. Gastrointestinal and Liver Physiology* **309**:G491–499 DOI 10.1152/ajpgi.00140.2015.

Chen W, Zhou Y, Zhi X, Ma T, Liu H, Chen BW, Zheng X, Xie S, Zhao B, Feng X, Dang X, Liang T. 2019. Delivery of miR-212 by chimeric peptide-condensed supramolecular nanoparticles enhances the sensitivity of pancreatic ductal adenocarcinoma to doxorubicin. *Biomaterials* **192**:590–600 DOI 10.1016/j.biomaterials.2018.11.035.

Chen Y, Zhang W, Yan L, Zhang P, Li J. 2020. miR-29a-3p directly targets Smad nuclear interacting protein 1 and inhibits the migration and proliferation of cervical cancer HeLa cells. *PeerJ* 8:e10148 DOI 10.7717/peerj.10148.

Deng F, Magee N, Zhang Y. 2017. Decoding the role of extracellular vesicles in liver diseases. *Liver Research* **1**:147–155 DOI 10.1016/j.livres.2017.11.003.

Deng F, Miller J. 2019. A review on protein markers of exosome from different bio-resources and the antibodies used for characterization. *Journal of Histotechnology* **42**:226–239 DOI 10.1080/01478885.2019.1646984.

De Santis CE, Fedewa SA, Sauer AGoding, Kramer JL, Smith RA, Jemal A. 2016. Breast cancer statistics, 2015: convergence of incidence rates between black and white women. *CA: A Cancer Journal for Clinicians* **66**:31–42 DOI 10.3322/caac.21320.

De Veirman K, Wang J, Xu S, Leleu X, Himpe E, Maes K, De Bruyne E, Van Valkenberg K, Menu E, Van Riet I. 2016. Induction of miR-146a by multiple myeloma cells in mesenchymal stromal cells stimulates their pro-tumoral activity. *Cancer Letters* **377**:17–24 DOI 10.1016/j.canlet.2016.04.024.

Di Pace AI, Tumino N, Besi F, Alicata C, Conti LA, Munari E, Maggi E, Vacca P, Moretta L. 2020. Characterization of human NK cell-derived exosomes: role of DNAM1 receptor in exosome-mediated cytotoxicity against tumor. *Cancer* **12**:661–676 DOI 10.3390/cancers12030661.

Dong M, How T, Kirkbride KC, Gordon KJ, Lee JD, Hempel N, Kelly P, Moeller BJ, Marks JR, Blobe GC. 2007. The type III TGF-beta receptor suppresses breast cancer progression. *Journal of Clinical Investigation* **117**:206–217 DOI 10.1172/jci29293.

Fan Y, Siklenka K, Arora SK, Ribeiro P, Kimmins S, Xia J. 2016. miRNet - dissecting miRNA-target interactions and functional associations through network-based visual analysis. *Nucleic Acids Research* **44**:W135–141 DOI 10.1093/nar/gkw288.

Fang WY, Kuo YZ, Chang JY, Hsiao JR, Kao HY, Tsai ST, Wu LW. 2020. The tumor suppressor TGFBR3 blocks lymph node metastasis in head and neck cancer. *Cancer* **12**:1375–1399 DOI 10.3390/cancers12061375.

Gao W, Lu X, Liu L, Xu J, Feng D, Shu Y. 2012. MiRNA-21: a biomarker predictive for platinum-based adjuvant chemotherapy response in patients with non-small cell lung cancer. *Cancer Biology & Therapy* **13**:330–340 DOI 10.4161/cbt.19073.

Hesari A, Moghadam SAGolrokh, Siasi A, Rahmani M, Behboodi N, Rastgar-Moghadam A, Ferns GA, Ghasemi F, Avan A. 2018. Tumor-derived exosomes: potential biomarker or therapeutic target in breast cancer? *Journal of Cellular Biochemistry* **119**:4236–4240 DOI 10.1002/jcb.26364.
Holloway CM, Easson A, Escallon J, Leong WL, Quan ML, Reedijk M, Wright FC, McCready DR. 2010. Technology as a force for improved diagnosis and treatment of breast disease. Canadian Journal of Surgery 53:268–277.

Hong BS, Ryu HS, Kim N, Kim J, Lee E, Moon H, Kim KH, Jin MS, Kwon NH, Kim S, Kim D, Chung DH, Jeong K, Kim K, Kim KY, Lee HB, Han W, Yun J, Kim JI, Noh DY, Moon HG. 2019. Tumor suppressor miRNA-204-5p regulates growth, metastasis, and immune microenvironment remodeling in breast cancer. Cancer Research 79:1520–1534 DOI 10.1158/0008-5472.CAN-18-0891.

Hou X, Yang L, Wang K, Zhou Y, Li Q, Kong F, Liu X, He J. 2021. HELLs, a chromatin remodeler is highly expressed in pancreatic cancer and downregulation of it impairs tumor growth and sensitizes to cisplatin by reexpressing the tumor suppressor TGFBR3. Cancer Medicine 10:350–364 DOI 10.1002/cam4.3627.

Huang DW, Sherman BT, Lempicki RA. 2009a. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Research 37:1–13 DOI 10.1093/nar/gkn923.

Huang DW, Sherman BT, Lempicki RA. 2009b. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nature Protocols 4:44–57 DOI 10.1038/nprot.2008.211.

Huang R, Gao L. 2018. Identification of potential diagnostic and prognostic biomarkers in non-small cell lung cancer based on microarray data. Oncology Letters 15:6436–6442 DOI 10.3892/ol.2018.8153.

Kanlikilicer P, Bayraktar R, Denizli M, Rashed MH, Ivan C, Aslan B, Mitra R, Karagoz K, Bayraktar E, Zhang X, Rodriguez-Aguayo C, El-Arabey AA, Kahraman N, Baydogan S, Ozkayar O, Gatza ML, Ozpolat B, Calin GA, Sood AK, Lopez-Berestein G. 2018. Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer. EBioMedicine 38:100–112 DOI 10.1016/j.ebiom.2018.11.004.

Kasinski AL, Slack FJ. 2011. Epigenetics and genetics, MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nature Reviews Cancer 11:849–864 DOI 10.1038/nrc3166.

Lian M, Zhang C, Zhang D, Chen P, Yang H, Yang Y, Chen S, Hong G. 2019. The association of five preoperative serum tumor markers and pathological features in patients with breast cancer. Journal of Clinical Laboratory Analysis 33:e22875 DOI 10.1002/jcla.22875.

Liu C, Yang Z, Deng Z, Zhou Y, Gong Q, Zhao R, Chen T. 2018. Upregulated lncRNA ADAMTS9-AS2 suppresses progression of lung cancer through inhibition of miR-223-3p and promotion of TGFBR3. IUBMB Life 70:536–546 DOI 10.1002/iub.1752.

Liu S, Wang W, Zhao Y, Liang K, Huang Y. 2020. Identification of potential key genes for pathogenesis and prognosis in prostate cancer by integrated analysis of gene expression profiles and the cancer genome Atlas. Frontiers in Oncology 10:809 DOI 10.3389/fonc.2020.00809.

Momen-Heravi F, Saha B, Kodys K, Catalano D, Satishchandran A, Szabo G. 2015. Increased number of circulating exosomes and their microRNA cargos are potential
novel biomarkers in alcoholic hepatitis. *Journal of Translational Medicine* **13**:261 DOI 10.1186/s12967-015-0623-9.

Nagy Á, Lánczyk A, Menyhárt O, Győrffy B. 2018. Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets. *Scientific Reports* **8**:9227 DOI 10.1038/s41598-018-27521-y.

Roy S, Hooiveld GJ, Seehawer M, Caruso S, Heinzmann F, Schneider AT, Frank AK, Cardenas DV, Sonntag R, Luedde M, Trautwein C, Stein I, Pikarsky E, Loosen S, Tacke F, Ringelhan M, Avsaroglu SK, Goga A, Buendia MA, Vucur M, Heikenwalder M, Zucman-Rossi J, Zender L, Roderburg C, Luedde T. 2018. microRNA 193a-5p regulates levels of nucleolar- and spindle-associated protein 1 to suppress hepatocarcinogenesis. *Gastroenterology* **155**:1951–1966e1926 DOI 10.1053/j.gastro.2018.08.032.

Russnes HG, Navin N, Hicks J, Borresen-Dale AL. 2011. Insight into the heterogeneity of breast cancer through next-generation sequencing. *Journal of Clinical Investigation* **121**:3810–3818 DOI 10.1172/jci57088.

Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, Simonovic M, Doncheva NT, Morris JH, Bork P, Jensen LJ, Mering CV. 2019. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. *Nucleic Acids Research* **47**:D607–D613 DOI 10.1093/nar/gky1131.

Théry C, Amigorena S, Raposo G, Clayton A. 2006. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. *Current Protocols in Cell Biology* Chapter 3, Unit 3.22 DOI 10.1002/0471143030.cb0322s30.

Uhlen M, Zhang C, Lee S, Sjöstedt E, Fagerberg L, Bidkhori G, Benfeitas R, Arif M, Liu Z, Edfors F, Sanli K, Feilitzen Kvon, Oksvold P, Lundberg E, Hobo S, Nilsson P, Mattsson J, Schwenk JM, Brunnströrm H, Glimelius B, Sjöblom T, Edqvist PH, Djureinovic D, Micke P, Lindskog C, Mardinoglu A, Ponten F. 2017. A pathology of the human cancer transcriptome. *Science* **357** DOI 10.1126/science.aan2507.

Wang J, Zheng Y, Zhao M. 2016. Exosome-based cancer therapy: implication for targeting cancer stem cells. *Frontiers in Pharmacology* **7**:533 DOI 10.3389/fphar.2016.00533.

Wei C, Gao JJ. 2019. Downregulated miR-383-5p contributes to the proliferation and migration of gastric cancer cells and is associated with poor prognosis. *PeerJ* 7:e7882 DOI 10.7717/peerj.7882.

Wu H, Zhu S, Mo YY. 2009. Suppression of cell growth and invasion by miR-205 in breast cancer. *Cell Research* **19**:439–448 DOI 10.1038/cr.2009.18.

Xu YJ, Yu H, Liu GX. 2020. Hsa_circ_0031288/hsa-miR-139-3p/Bcl-6 regulatory feedback circuit influences the invasion and migration of cervical cancer HeLa cells. *Journal of Cellular Biochemistry* **121**:4251–4260 DOI 10.1002/jcb.29650.

Yu G, Xiong D, Liu Z, Li Y, Chen K, Tang H. 2019. Long noncoding RNA LINC00052 inhibits colorectal cancer metastasis by sponging microRNA-574-5p to modulate CALCOCO1 expression. *Journal of Cellular Biochemistry* **120**:17258–17272 DOI 10.1002/jcb.28988.
Zhou Y, Ren H, Dai B, Li J, Shang L, Huang J, Shi X. 2018. Hepatocellular carcinoma-derived exosomal miRNA-21 contributes to tumor progression by converting hepatocyte stellate cells to cancer-associated fibroblasts. Journal of Experimental & Clinical Cancer Research 37:324 DOI 10.1186/s13046-018-0965-2.